EMA/122333/2019

European Medicines Agency decision
P/0106/2019

of 22 March 2019

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for mavacamten (EMEA-002231-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0106/2019

of 22 March 2019

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the
granting of a waiver for mavacamten (EMEA-002231-PIP01-17) in accordance with Regulation (EC) No

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of
12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC)

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of
31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal
products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by MyoKardia, Inc. on 22 January 2018 under Article 16(1)
of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a
waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on
1 February 2019, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said
Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the
agreement of a paediatric investigation plan and on the granting of a deferral and on the
granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for mavacamten, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for mavacamten, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for mavacamten, capsule, hard, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This decision is addressed to MyoKardia, Inc., 333 Allerton Ave., CA 94080 - South San Francisco, USA.
Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver
EMEA-002231-PIP01-17

Scope of the application

Active substance(s):
Mavacamten

Condition(s):
Treatment of hypertrophic cardiomyopathy

Pharmaceutical form(s):
Capsule, hard

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
MyoKardia, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, MyoKardia, Inc. submitted for agreement to the European Medicines Agency on 22 January 2018 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 27 February 2018.

Supplementary information was provided by the applicant on 22 October 2018. The applicant proposed modifications to the paediatric investigation plan.
Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   • to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   • to grant a deferral in accordance with Article 21 of said Regulation;
   • to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)
1. Waiver

1.1. **Condition:**

Treatment of hypertrophic cardiomyopathy

The waiver applies to:

- the paediatric population from birth to less than 12 years;
- capsule, hard, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. **Condition:**

Treatment of hypertrophic cardiomyopathy

2.1.1. **Indication(s) targeted by the PIP**

Treatment of obstructive hypertrophic cardiomyopathy

2.1.2. **Subset(s) of the paediatric population concerned by the paediatric development**

From 12 to less than 18 years of age

2.1.3. **Pharmaceutical form(s)**

Capsule, hard

2.1.4. **Measures**

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of measures</th>
<th>Description</th>
</tr>
</thead>
</table>
| Quality-related studies | 2                  | **Study 1**
|                     |                    | Development of an oral lower strength dose                                   |
|                     |                    | **Study 2**
|                     |                    | Assessment of compatibility with food and drinks                             |
| Non-clinical studies | 0                  | Not applicable                                                              |
| Clinical studies    | 1                  | **Study 3**
|                     |                    | Double-blind, randomised, placebo controlled trial to evaluate the activity, safety and tolerability of mavacamten in children from 12 to less than 18 years of age with obstructive hypertrophic cardiomyopathy |
Extrapolation, modelling and simulation studies | 2 | **Study 4**
Modelling and simulation study to derive dosing of mavacamten for use in adolescents from 12 to less than 18 years of age with obstructive hypertrophic cardiomyopathy

**Study 5**
Modelling and simulation study to document the PK and PD data relationship in adolescents from 12 to less than 18 years of age with obstructive hypertrophic cardiomyopathy

| Other studies | 0 | Not applicable |
| Other measures | 0 | Not applicable |

### 3. Follow-up, completion and deferral of PIP

| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By March 2029 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |